Get started
Oramed Pharmaceuticals Inc.Oramed Pharmaceuticals Inc.Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with Oramed Pharmaceuticals Inc.



Key stats


Market capitalization
‪197.17 M‬ USD
Dividend yield (indicated)
0.00%
Price to earnings Ratio (TTM)
1.14
Basic EPS (TTM)
4.23 USD
Net income (FY)
‪63.24 M‬ USD
Revenue (FY)
‪2.00 M‬ USD
Shares float
‪33.96 M‬
Beta (1Y)
0.60

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
13
Change (1Y)
0
Revenue / Employee (1Y)
‪153.85 K‬ USD
Net income / Employee (1Y)
‪4.86 M‬ USD

Company info


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Nadav Kidron
Website
oramed.com
Headquarters
New York
Founded
2002
IPO date
Apr 1, 2002
ISIN
US68403P2039
CUSIP
68403P203
FIGI
BBG000LRYR36
Identifiers
ISIN US68403P2039
CFI code
ESVUFR
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


IWC
iShares Microcap ETF
Weight0.04%
Market value‪548.80 K‬
TCH.F85
Tachlit SAL (40) TA Growth
Weight0.87%
Market value‪193.12 K‬
KSM.F75
KSM ETF (4A) TA Global-BlueTech Units
Weight0.59%
Market value‪86.13 K‬
KSM.F21
KSM ETF (4A) TA-Growth
Weight0.87%
Market value‪35.82 K‬
OMFS
Invesco Russell 2000 Dynamic Multifactor ETF
Weight0.01%
Market value‪33.40 K‬
MTF.F18
MTF SAL (4A) TA Tech - Elite IL
Weight0.11%
Market value‪28.03 K‬
FSEV
Fidelity Enhanced Small Cap Value ETF
Weight0.06%
Market value‪3.62 K‬

Explore more ETFs 

Frequently asked questions


The current price of ORMP is 4.74 USD — it has increased by 1.50% in the past 24 hours. Watch Oramed Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oramed Pharmaceuticals Inc. stocks are traded under the ticker ORMP.
ORMP stock has fallen by −1.46% compared to the previous week, the month change is a −1.86% fall, over the last year Oramed Pharmaceuticals Inc. has showed a 108.81% increase.
We've gathered analysts' opinions on Oramed Pharmaceuticals Inc. future price: according to them, ORMP price has a max estimate of 7.00 USD and a min estimate of 7.00 USD. Watch ORMP chart and read a more detailed Oramed Pharmaceuticals Inc. stock forecast: see what analysts think of Oramed Pharmaceuticals Inc. and suggest that you do with its stocks.
ORMP reached its all-time high on Jan 13, 2014 with the price of 31.73 USD, and its all-time low was 0.09 USD and was reached on Apr 2, 2004. View more price dynamics on ORMP chart.
See other stocks reaching their highest and lowest prices.
ORMP stock is 4.12% volatile and has beta coefficient of 0.60. Track Oramed Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is Oramed Pharmaceuticals Inc. there?
Today Oramed Pharmaceuticals Inc. has the market capitalization of ‪197.17 M‬, it has decreased by −9.18% over the last week.
Yes, you can track Oramed Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Oramed Pharmaceuticals Inc. is going to release the next earnings report on Nov 16, 2026. Keep track of upcoming events with our Earnings Calendar.
ORMP earnings for the last quarter are 2.76 USD per share, whereas the estimation was 0.43 USD resulting in a 541.86% surprise. The estimated earnings for the next quarter are 0.43 USD per share. See more details about Oramed Pharmaceuticals Inc. earnings.
Oramed Pharmaceuticals Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ORMP net income for the last quarter is ‪78.16 M‬ USD, while the quarter before that showed ‪38.31 M‬ USD of net income which accounts for 0.00% change. Track more Oramed Pharmaceuticals Inc. financial stats to get the full picture.
As of Sep 21, 2026, the company has 13 employees. See our rating of the largest employees — is Oramed Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Oramed Pharmaceuticals Inc. EBITDA is ‪−14.40 M‬ USD, and current EBITDA margin is −748.35%. See more stats in Oramed Pharmaceuticals Inc. financial statements.
Like other stocks, ORMP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oramed Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oramed Pharmaceuticals Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oramed Pharmaceuticals Inc. stock shows the buy signal. See more of Oramed Pharmaceuticals Inc. technicals for a more comprehensive analysis.